R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics

Share

Gaining new market segments in clinical diagnostics – globally unique position as system supplier in laboratory diagnostics sector

AusDiagnostics is now part of R-Biopharm.
AusDiagnostics is now part of R-Biopharm.

R-Biopharm AG, a leading German biotechnology company operating on a global scale, announced the acquisition of AusDiagnostics. R-Biopharm is expanding its product portfolio with the addition of the Australian specialist and manufacturer of molecular biology multiplex diagnostics, extraction reagents, and laboratory automation equipment. The company is thereby unlocking new market segments in clinical diagnostics and continuing on its path of steady internationalization. “The existing and future molecular biology multiplex analysis platforms for syndrome testing from system supplier AusDiagnostics broadens our molecular biology expertise and perfectly complements our present clinical diagnostics portfolio,” states Christian Dreher, CEO of R-Biopharm. “The acquisition strengthens our position as a reliable partner for system solutions and offers our customers additional options for diagnostics.”

Upon its establishment in 2006, the Australian company introduced its patented Multiplex Tandem PCR (MT-PCR) on the market. The current technology allows the simultaneous detection of up to 24 pathogens or resistance genes from a single sample, thus shortening the lengthy test procedure in human and animal diagnostics as well as environmental, agricultural, and food analysis. The analysis platform is used in laboratories and hospitals throughout the world for detecting a broad range of diseases.

AusDiagnostics CEO Scott Gilroy said that the transaction marked an exciting new chapter for the company: “Both AusDiagnostics and R-Biopharm AG share the same commitment to innovation in the biotechnology space. This acquisition strengthens AusDiagnostics and will accelerate our global presence. We’ve experienced tremendous, industry-leading growth over the past two years, which has been underpinned by our broad suite of innovative products, talented team, and incredible, loyal customers. Joining the R-Biopharm group will allow us to further build on this and continue to deliver exceptional products and service for our Australian and international customers.”

AusDiagnostics currently has 92 employees with offices in New Zealand, the USA, and Great Britain. Its production facilities in Australia and Great Britain supply a steadily growing network of more than 25 distributors and partners around the world – from which R-Biopharm expects further synergy effects for production as well as international service and support in its clinical diagnostics line.

Press contact:

 

Simone Feiler

Head of Corporate Brand Communication

https://r-biopharm.com/

https://r-biopharm.com/news-press/download-gallery/

R-Biopharm AG

An der neuen Bergstraße 17

64297 Darmstadt, Germany

Tel.: +49 61 51 - 81 02-538

Mobile: +49 160 - 55 273 60

Fax: +49 61 51 - 81 02-40

Email: s.feiler@r-biopharm.de

Images

AusDiagnostics is now part of R-Biopharm.
AusDiagnostics is now part of R-Biopharm.
Download

About R-Biopharm AG

R-Biopharm AG



R-Biopharm AG, located in Darmstadt, is one of Germany’s leading biotechnology companies. It considers itself as a pioneer for health and quality of life. The compa­ny´s aspiration is to provide the highest possible precision, safety, clarity and certainty with excellent products and solutions – in prevention, therapy and healing. Research and development at R-Biopharm has developed agile processes in order to take on new challenges to accompany a steadily growing world population into a new health era with sustainable solutions.

As an internationally recognized leader, R-Biopharm stands for the development of excellent technologies, products and solutions in the fields of Clinical Diagnostics, Nutrition Care and Food and Feed Analytics. R-Biopharm is the global market leader for test systems in the field of allergen analysis. The biotechnology company is known for its products that are of high importance for human health. To this end, it unites development, production and sales under one roof and is successfully represented in more than 120 countries worldwide – through 28 subsidiaries and 120 distributors. Founded in 1988, the family-run company employs a total of around 1,300 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the “Sustainability Award” for sustainable and profitable growth. R-Biopharm is cultivating a value-oriented corporate culture and management and is family-run in the second generation. The Chairman of the Board of Directors is Christian Dreher.

Subscribe to releases from R-Biopharm AG

Subscribe to all the latest releases from R-Biopharm AG by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from R-Biopharm AG

R-Biopharm announces test to detect monkeypox virus1.6.2022 13:27:17 CEST | Press release

Test for research purposes available soon R-Biopharm AG, a leading and globally operating biotechnology company based in Germany, will soon launch a test for the detection of monkeypox virus. The real-time PCR test, developed for research purposes (RUO), shall contribute to track and control the epidemiological spread of the virus. The product is expected to be available in approximately two to three weeks under the name RIDA®GENE Monkeypox Virus RUO (part number PG4915RUO). Like the test for the detection of the SARS-CoV-2 virus, which was the first to be launched by a German company for research purposes in February 2020 and was officially approved for the diagnosis of SARS-CoV-2 in the fall of 2020 with the CE mark, the real-time PCR test for the detection of monkeypox virus will also be usable on all common real-time PCR instruments. The uniform RIDA®GENE design also allows users to run this test together with other RIDA®GENE products. "R-Biopharm cares about the common good," says

R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation7.12.2021 13:35:22 CET | Press release

R-Biopharm, an international specialist in clinical diagnostics, announces that the company’s RIDA®GENE Flu & SARS-CoV-2 multiplex test (PG6825) has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) Regulations 2021 (“CTDA”). R-Biopharm will now work to resume the sale of the product in the UK. RIDA®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRpgene in all currently known variants and mutations of the COVID 19 virus. Only validated products, or produc